Anamorelin: Research Profile and WADA 2026 Status Update
The WADA 2026 Prohibited List explicitly names anamorelin under S2 growth hormone secretagogues. This profile covers its GHS-R1a mechanism, the ROMANA Phase III cachexia data, and its current regulatory standing across jurisdictions.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
The WADA 2026 Prohibited List, which entered force on January 1, 2026, added clarifying language to the S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) category that explicitly names anamorelin alongside other growth hormone secretagogues banned at all times in competitive sport. This update prompts a closer look at anamorelin's pharmacology, the clinical evidence base underlying its development, and the regulatory landscape that shapes how researchers approach it today.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Background and mechanism of action
Anamorelin is an orally bioavailable, selective agonist of the ghrelin receptor (GHS-R1a), the same receptor activated by endogenous ghrelin. Unlike injectable growth hormone-releasing peptides such as ipamorelin or GHRP-6, anamorelin was developed as a once-daily oral compound specifically to address cancer-associated cachexia — the progressive loss of skeletal muscle and adipose tissue that accompanies advanced malignancies.
At the receptor level, anamorelin binds GHS-R1a expressed on hypothalamic neurons and pituitary somatotrophs. This binding activates the orexigenic neuropeptide Y/agouti-related peptide (NPY/AgRP) axis, promoting appetite signaling and increasing caloric intake. Simultaneously, anamorelin attenuates the production of pro-inflammatory cytokines — specifically IL-6 and TNF-α — that drive the catabolic milieu characteristic of cachexia. A secondary anabolic effect arises from pituitary GHS-R1a stimulation, where anamorelin stimulates pulsatile growth hormone release, contributing to lean body mass preservation independent of its appetite effects.
The dual anti-inflammatory and anabolic signaling profile distinguishes anamorelin from simpler appetite stimulants and explains its selection as a candidate in oncology cachexia trials over the past two decades.
ROMANA Phase III programme
The largest published dataset on anamorelin comes from the ROMANA 1 and ROMANA 2 Phase III randomised controlled trials, the results of which were reported in The Lancet Oncology in 2016. Both trials enrolled patients with unresectable stage III or IV non-small cell lung cancer (NSCLC) and cancer cachexia, randomised to anamorelin 100 mg once daily versus placebo over twelve weeks.
Pooled results from the ROMANA programme documented statistically significant improvements in lean body mass and total body weight relative to placebo controls. Reported lean body mass gains ranged from approximately 0.5 to 1.5 kg advantage over placebo by week twelve. Handgrip strength, a secondary endpoint used as a functional proxy for muscle quality, did not reach statistical significance in all cohorts — a finding that has guided subsequent research into whether mass and function dissociate under GHS-R1a stimulation.
A 2026 umbrella review of systematic reviews examining pharmacological treatments for cancer-related anorexia-cachexia syndrome (PMID 41950300) positioned anamorelin among the agents with the strongest lean body mass evidence across multiple cancer types, including gastric and pancreatic cohorts beyond NSCLC.
Regulatory and compounding status
Anamorelin's regulatory standing varies considerably by jurisdiction. In Japan, anamorelin received approval in 2021 under the trade name Adlumiz for treatment of cancer cachexia in patients with NSCLC, gastric cancer, pancreatic cancer, or colorectal cancer — making it one of the few peptide-class cachexia drugs with full marketing authorisation anywhere in the world. In the United States, anamorelin has not received FDA approval and remains classified as an investigational compound. Its 503A compounding status in the US is under review by the FDA Pharmacy Compounding Advisory Committee, meaning it has not been definitively placed on either the Category 1 (permissible) or Category 2 (not permissible) lists at the time of this writing.
In the European Union, the EMA reviewed anamorelin and did not grant authorisation following its marketing application, citing the functional endpoint data gap noted above.
WADA 2026 classification and research implications
WADA's 2026 Prohibited List classifies anamorelin under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics, within the subcategory of growth hormone secretagogues and their mimetics. This classification is in-competition and out-of-competition, placing it in the highest restriction tier. Anamorelin is designated a "non-specified substance," which means the standard of proof applied to adverse analytical findings under the World Anti-Doping Code is not reduced for contamination arguments.
The 2026 update added specific named examples to the S2 category to address detection ambiguity that had accumulated as novel GHS compounds entered the research literature. Anamorelin's explicit naming — alongside compounds such as ibutamoren (MK-677) and ipamorelin — reflects WADA's intent to close definitional gaps that might otherwise create uncertainty about whether an orally administered GHS-R1a agonist is captured by the peptide hormones category.
For researchers working with samples from athletic populations, this classification means anamorelin will be included in standard WADA-accredited laboratory screening panels. Detection methods for GHS-R1a agonists have advanced substantially; urine and dried blood spot immunoassay screens now routinely cover this compound class. Studies examining pharmacokinetics relevant to doping control have characterised urinary metabolite profiles enabling retrospective detection windows of approximately 24 to 48 hours for parent compound and up to several days for certain metabolites, depending on dosing and matrix.
Cross-reference
Full compound data, including primary citation links and structural annotations, is available on the Anamorelin library profile.
Cited studies
- PMID 41950300 — "Pharmacological Treatments for Cancer-Related Anorexia-Cachexia Syndrome: An Umbrella Review of Systematic Reviews and Meta-Analyses." (PROSPERO registration CRD420251131074, 2026). https://doi.org/10.1016/S1470-2045(16)00023-2
- ROMANA 1 / ROMANA 2 pooled data — Temel JS et al., The Lancet Oncology, 2016. Phase III randomised trials of anamorelin 100 mg once daily versus placebo in NSCLC patients with cachexia.
- WADA 2026 Prohibited List — World Anti-Doping Agency, S2 category, effective January 1, 2026. https://www.wada-ama.org/en/prohibited-list
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.